Loading financials from SEC filings…
Drug manufacturers · Healthcare · Fiscal year ends Dec 31
Kiniksa Pharmaceuticals International reported revenue of $678M in the fiscal year ended Dec 2025, up 60.1% from the year before. Operating income was $77M, an operating margin of 11.4%, and net income was $59M. Operating cash flow of $138M less capital expenditure of $2M left free cash flow of $136M.
Ranks among the 78 drug manufacturers companies we cover (1st = best; for debt, the least indebted). Green = top third, red = bottom third.
Last 5 fiscal years
| Fiscal year | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 38.5 | 220 | 270 | 423 | 678 |
| Cost of revenue | 9.1 | 22.9 | 33.4 | 60.9 | 77.7 |
| Gross profit | 29.4 | 197 | 237 | 362 | 600 |
| Research & development | 99.3 | 65.5 | 76.1 | 112 | 96.9 |
| Selling, general & admin | 85.9 | 98.0 | 129 | 168 | 196 |
| Operating income | −157 | 9.8 | −25.2 | −45.6 | 77.2 |
| Pre-tax income | −157 | 11.0 | −16.7 | −36.2 | 88.9 |
| Income tax | 1.4 | −172 | −30.7 | 7.0 | 29.9 |
| Net income | −158 | 183 | 14.1 | −43.2 | 59.0 |
| Diluted EPS | −2.30 | 2.60 | 0.20 | −0.60 | 0.75 |
| Diluted shares | 68.6 | 70.4 | 71.9 | 71.4 | 79.0 |
| Fiscal year | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|
| Cash & equivalents | 122 | 123 | 108 | 184 | 166 |
| Receivables | 4.0 | 12.7 | 21.3 | 41.7 | 15.6 |
| Inventory | 3.7 | 21.6 | 31.1 | 26.4 | 54.9 |
| Current assets | 196 | 243 | 276 | 332 | 527 |
| Net PP&E | 2.8 | 1.7 | 0.7 | 0.7 | 1.9 |
| Total assets | 233 | 460 | 526 | 581 | 764 |
| Payables | 1.9 | 7.9 | 8.2 | 2.0 | 2.0 |
| Deferred revenue | – | 12.0 | 0.3 | – | – |
| Current liabilities | 44.8 | 47.1 | 63.7 | 101 | 139 |
| Total liabilities | 47.8 | 63.5 | 87.5 | 142 | 196 |
| Shareholders' equity | 185 | 396 | 439 | 438 | 568 |
| Fiscal year | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|
| Operating cash flow | −126 | 5.8 | 13.3 | 25.7 | 138 |
| Capital expenditure | 0.4 | 0.1 | 0.1 | 0.3 | 1.6 |
| Free cash flow | −127 | 5.7 | 13.2 | 25.4 | 136 |
| Depreciation & amortisation | 2.4 | 2.4 | 2.3 | 1.7 | 1.6 |
| Stock-based compensation | 25.2 | 25.1 | 27.1 | 30.7 | 37.0 |
| Fiscal year | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|
| Revenue growth (YoY) | – | 471.2% | 22.7% | 56.6% | 60.1% |
| Operating income growth (YoY) | – | – | −357.8% | – | – |
| EPS growth (YoY) | – | – | −92.3% | −400.0% | – |
| Gross margin | 76.4% | 89.6% | 87.6% | 85.6% | 88.5% |
| Operating margin | −406.4% | 4.4% | −9.3% | −10.8% | 11.4% |
| Net margin | −409.7% | 83.3% | 5.2% | −10.2% | 8.7% |
| Return on equityBlank when equity is negative | −85.3% | 46.3% | 3.2% | −9.9% | 10.4% |
| ROCEEBIT ÷ (assets − current liabilities) | −83.3% | 2.4% | −5.4% | −9.5% | 12.4% |
| Free cash flow margin | −328.7% | 2.6% | 4.9% | 6.0% | 20.1% |
| Cash conversion (CFO ÷ net income) | 0.80x | 0.03x | 0.94x | −0.59x | 2.34x |
| Receivable days | 38 | 21 | 29 | 36 | 8 |
| Inventory days | 147 | 344 | 340 | 158 | 258 |
| Payable days | 75 | 126 | 90 | 12 | 10 |
| Current ratio | 4.38x | 5.16x | 4.34x | 3.30x | 3.79x |
Standardised figures from the company's XBRL filings with the SEC (10-K, 10-Q). Line items follow US GAAP tags, so a company's own statement layout may differ and some lines show “–” where the company does not report that item. Ratios are calculated from these figures. For education only; not investment advice or a recommendation.